Trial Profile
MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Filgrastim; Melphalan
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Therapeutic Use
- Acronyms MUKnineb; OPTIMUM; UK OPTIMUM
- 12 Dec 2023 Results assessing characterise factors associated with early progression, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 28 Sep 2023 According to a SkylineDx media release, company announced that a new peer-reviewed publication will be presented during the International Myeloma Society 20th Annual Meeting highlighting the significant impact of SKY92 in identifying high-risk multiple myeloma patients who will benefit from an intensified treatment combination with improved survival.
- 23 Jun 2023 According to The Institute of Cancer Research media release, results from this trial were published in the Journal of Clinical Oncology.